Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Oncologist
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups
Oncologist 2019 Oct 10;[EPub Ahead of Print], G Macchia, R Lazzari, N Colombo, C Laliscia, G Capelli, GR D'Agostino, F Deodato, E Maranzano, E Ippolito, S Ronchi, F Paiar, M Scorsetti, S Cilla, R Ingargiola, A Huscher, AM Cerrotta, A Fodor, L Vicenzi, D Russo, S Borghesi, E Perrucci, S Pignata, C Aristei, AG Morganti, G Scambia, V Valentini, BA Jereczek-Fossa, G FerrandinaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.